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Abstract
The complexity of the human proteome is greatly expanded by post-translational modifications. New
tools capable of recognizing these modifications in a sequence-specific fashion provide a route to
purify these modified proteins, to alter protein trafficking, and to visualize signal transduction in real
time. Here, we have evolved novel, modification-specific ligands that target phosphorylated IκBα.
To do this, we employed mRNA display-based in vitro selection using a 30-trillion-member protein
library based on the fibronectin type III domain. The selection yielded one fibronectin molecule,
10C17C25, that binds a phospho-IκBα peptide with Kd = 18 nM and is over 1000-fold specific
compared to the nonphosphorylated peptide. 10C17C25 specifically recognizes endogenous
phosphorylated IκBα from mammalian cell extract and stabilizes phospho-IκBα in vivo. We also
incorporated 10C17C25 into a FRET indicator that detects IκB kinase (IKK) activity in vitro,
demonstrating the utility of selecting designed adaptors for kinase activity sensors.
Whereas the human genome contains less than 25,000 genes, the proteome likely contains over
1,000,000 different proteins when alternative splicing and post-translational modifications
(PTM) are taken into account (1). Post-translational modifications are essential to cellular
signaling, and the ability to detect and quantitate modifications is challenging but immensely
valuable. Nucleic-acid-based microarrays are powerful proteomic tools, although they cannot
detect the presence and extent of PTMs and may not be accurate predictors of protein quantities
(2). Attempts to generate open-access resources for modification-specific affinity reagents to
all proteins are currently under way (3). In addition to detection in vitro, novel protein affinity
reagents that are functional in the intracellular environment are also useful for determining
protein localization and for assessing protein function (4,5). Compared to gene and transcript
knockout techniques, domain and state-specific protein binders that knock down activity may
be better determinants of protein function (6). Increasingly, in vitro selection techniques such
as ribosome display and mRNA display are being implemented to generate novel protein-based
affinity reagents with alternative scaffolds (7–9). Nonimmunoglobulin scaffolds such as the
ankyrin-based “DARPins” (10) and fibronectin type III “monobodies” (11) have advantages
over antibodies for both in vitro and in vivo applications because they (i) lack disulfide bonds,
(ii) can be expressed efficiently in bacteria and eukaryotic cells, and (iii) possess improved
stability (12).
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Intrinsically unstructured domains compose a large fraction of the proteome, and many are
subjected to PTM (1,13). An example of such a domain is the N-terminus of IκB. In the classical
NF-κB pathway, three IκB proteins, IκBα, β, and ∈, regulate the activity of the ubiquitous
transcription factor NF-κB (14). NF-κB plays an important role in inflammation and is
implicated in autoimmune disease and cancer (15). Upon stimulation, IκB kinase (IKK)
immediately phosphorylates IκBα at serines 32 and 36 (16,17). IκBα is then ubiquitinated by
the SCF-βTrCP E3 ligase complex and degraded by the proteasome, thereby freeing NF-κB
to direct transcription (18). Reagents that detect or inhibit the degradation of IκBα in vivo may
be useful in order to understand the many complex pathways to NF-κB activation. Inhibition
at this control point is ideal since the functions of IKK and βTrCP are not specific to the classical
NF-κB pathway (15,19).
We employed in vitro selection by mRNA display to generate novel protein affinity reagents
that recognize phosphorylated IκBα specifically. We utilized a combinatorial protein library
based on the 10th fibronectin type III domain of human fibronectin (10FnIII) to generate protein
molecules that are functional both in vitro and in vivo (20). The target used for this selection
was a synthetic phospho-peptide corresponding to amino acid residues 22–41 of human
IκBα. This peptide contains the E3 ligase recognition sequence including phosphorylated
serines 32 and 36, which are essential for degradation. The target peptide contained an N-
terminal biotin spaced by aminohexanoic acid for specific immobilization to either neutravidin
agarose or streptavidin acrylamide beads.
The first round of selection was carried out so that the first affinity enrichment step contained
at least three copies of the 30-trillion-member 10FnIII library (21). Enrichment was monitored
by measuring radiolabeled fusion binding (Figure 1, panel a). In order to reduce the enrichment
of bead binders, a negative selection step was employed at round 6. After 10 rounds of selection,
pool 10 was determined to have approximately 50% binding efficiency at RT with relatively
low background binding (1%). Figure 1 (panel b) demonstrates that pool 10 binding is both
sequence-specific and phospho-specific. Binding to a nonphosphorylated IκBα peptide
otherwise identical to the target was equal to background. Likewise, phospho-serines alone are
not sufficient for binding. No binding was detected above background to a peptide
corresponding to Elk1 residues 380–394 containing two phosphorylated serines.
Pool 10 was cloned, and 11 sequences were obtained. All 11 sequences were highly similar,
suggesting that all sequences share a common ancestor (see Supporting Information). One
representative sequence, 10C17, is illustrated in Figure 2, panel a. The wild-type sequence
shown represents a 7-residue deletion mutant previously described as 10FnIII (Δ1–7) and has
equivalent expression, solubility, and folding stability as full-length 10FnIII (20). Essentially,
only one solution to the molecular recognition of phospho-IκBα was obtained. This may be
due to an intrinsic rarity of binders in the library, as obtaining binders to non-structured targets
may be more difficult than obtaining binders to structured targets. Alternatively, it is possible
that the pool reached an artificial bottleneck due to overly stringent selection conditions or that
the immobilization scheme on streptavidin beads limited accessibility of the target.
The ability for the binders to express in bacteria is important for their utility as affinity reagents.
Both 10C17 and another pool 10 clone, 10C19, do not express well in E. coli BL21(DE3) (data
not shown). In order to improve the expression of 10C17, solubility was evolved using the
GFP reporter screen developed by Waldo et al. (22). Three rounds of evolution (A, B, and C)
were performed using error-prone PCR so that one or two mutations were generated per gene.
Representative sequences obtained from each of the three rounds of evolution performed are
listed in Figure 2, panel a. Approximately 2000 colonies were screened in each round, and the
brightest 24 colonies were picked and assayed. The improvement in expression was analyzed
by comparing total cell fluorescence of 10C17-GFP variants relative to that of WT 10FnIII
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(Figure 2, panel b). For the first two rounds of evolution, expression was induced with IPTG
for 4 h (screen 1). We found that although the initial mutations improved expression, the result
of the long induction was that fluorescent aggregates were able to accumulate. This resulted
in obtaining variants that performed better than wild-type (WT) 10FnIII in the assay but did
not express as well. We found that decreasing the length of expression to 1.5 h improved the
sensitivity of the screen (Figure 2, panel b, screen 2). In order to ensure that function was
retained, binding was measured for each of the variants using SDS-PAGE quantitated by
autoradiography (Figure 2, panel c).
From round one of the evolution, one variant containing two mutations was obtained (A21)
that improved both solubility and binding (Figure 2). Two sequences were obtained from round
two that improved solubility and did not affect binding. B11 was a unique clone, whereas the
B01 sequence was found three times out of the 24 clones assayed. We created 10C17B25 by
combining the two beneficial point mutations selected, L13Q and A10T, from B11 and B01,
respectively. 10C17B25 displays an additive improvement in solubility. The third round of
evolution again generated two variants both with improved expression (C21, which was found
twice, and C22, which was unique). The two mutations selected in C21 and C22 were combined
to produce 10C17C25, which binds with approximately 94% efficiency (Figure 2, panels a and
c). This variant could be expressed at modest levels in bacteria (1 mg L−1 culture) and was
purified by nickel affinity and ion exchange chromatography.
The fact that we obtained improvements in both solubility and binding argues that the mutations
increased the overall stability of the domain. Of the six mutations we implemented to obtain
the 10C17C25 variant, only four positions differ from WT 10FnIII. Two mutations were
obtained at position Val6 (originally Ala in WT 10FnIII), V6D and D6E. Also, Ala10 reverted
back to Thr, the wild-type residue (Figure 2, panel a). Mutations V6E and L13Q are notable
because they are both likely solvent-exposed and close in space (Figure 2, panel d) (23). At
these two positions, the mutations altered what had been a large hydrophobic patch on the
protein surface, making it more polar with residues that have the potential to interact favorably.
In addition to these positive mutations, we also found changes that improved solubility but
negatively affected function (for example, variants B16 and C18, which were found three and
six times out of 24 clones in pools B and C, respectively).
We next addressed the affinity and specificity of 10C17C25, as well as its ability to bind
endogenous phospho-IκBα from human cell culture (Figure 3). 10C17C25 was subcloned into
a modified pET 21 vector that generates a C-terminal MBP fusion with a C-terminal His-tag.
MBP was used to increase the expression of 10C17C25 (45 mg L−1 culture) and provide an
additional affinity purification tag. Binding to both the phosphorylated and nonphosphorylated
IκBα peptides was measured using a Biacore T100 instrument (Figure 3, panels a and b).
10C17C25-MBP binds phospho-IκBα with Kd = 18 nM, which is comparable to high-affinity
antibodies (24). Binding to the nonphosphorylated peptide was not detected at the highest
concentration of 10C17C25-MBP tested (28 μM) (Figure 3, panel b). Therefore, the specificity
of 10C17C25 for the phosphorylated state is >1000-fold.
We next wanted to determine whether 10C17C25 is able to recognize wild-type, full-length
IκBα specifically in its phosphorylated state. Phospho-IκBα was produced in 293T cells by
stimulation with TNF-α and was stabilized by addition of the protease inhibitor calyculin A
and the proteasome inhibitor MG132. Both stimulated and unstimulated cells were lysed with
Tris-buffered saline plus 1% triton x-100. 10C17C25-MBP was added to the cleared lysates
and incubated with nickel-NTA beads. A Western blot performed to detect the presence of
IκBα using a polyclonal antibody demonstrates that 10C17C25 is able to bind full-length
IκBα only from TNF-α stimulated cells (Figure 3, panel c). IκBα that is immobilized by
10C17C25 has a noticeable reduction in mobility typical of phosphorylated IκBα (16).
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We also tested the ability of 10C17C25 to express and function in human cells. 10C17C25 was
cloned into a modified pIRES-puro vector containing a C-terminal GFP. This fusion protein
was well-expressed throughout the cytoplasm and nucleus of 293T cells when transiently
transfected. 10C17C25-GFP is able to stabilize phospho-IκBα in vivo when transiently
expressed (Figure 3, panel d). Expression of 10C17C25-GFP stabilizes phospho-IκBα even
after 30 min of TNF-α incubation, when IκBα degradation is maximal in 293T cells. Phospho-
IκBα is not detected in cells expressing Fn04, a nonselected fibronectin control, as phospho-
IκBα is rapidly degraded without an inhibitor present (Figure 3, panel d).
FRET sensors have been employed to detect PTMs reversibly in vivo in a spatial and temporal
manner (25–27). The sensors previously developed utilize natural modification-specific
binding domains such as SH2 and a chromodomain. These sensors contain an enzyme substrate
sequence that is bound by the proximal binding domain upon modification when signaling is
active. This binding restrains the sensor, resulting in a change in FRET between an N-terminal
CFP and a C-terminal YFP. The potential for such sensors can be greatly expanded by applying
in vitro selection to create novel modification-specific binding domains. We demonstrated this
by creating a FRET-based sensor for IKK activity and assessed its function in vitro (Figure 4,
panel a). CFP, YFP, and a new multiple cloning site that contains a flexible linker sequence
were cloned into a pET21 (His)6-tag vector (see Supporting Information). 10C17C25 and a
Klenow extended fragment encoding IκBα residues 23–41 were cloned into the vector in two
orientations with short and long linkers (Figure 4, panel b). The second orientation (IKK FS
C25 2S and 2L) contains longer linkers than the first (IKK FS C25 1S and 1L) due to the
location of the binding surface relative to the termini of the fibronectin domain. A nonselected
fibronectin variant was also cloned into one orientation as a control (IKK FS Fn04 control).
The five constructs were expressed in E. coli BL21(DE3) and purified by nickel-NTA affinity
chromatography. The constructs were phosphorylated in vitro with recombinant IKK-β, and
the reactions were terminated by addition of EDTA after 1 h. FRET was then measured on
constructs with or without incubation with IKK-β (Figure 4, panel c). FRET was quantitated
by measuring the ratio of the YFP emission intensity and the CFP emission intensity after
excitation at λ = 435 nm and is represented as a percent change after incubation with kinase
(Figure 4, panel b). The first orientation results in a small decrease in FRET after IKK-β
incubation, whereas the second orientation results in a substantial increase in FRET. The length
of the linker does not significantly affect the change in FRET, and phosphorylation of the
control sensor does not result in a change in FRET. This indicates that neither phosphorylation
alone nor interaction with IKK-β can account for the changes in FRET observed with IKK FS
C25 2S and 2L. Likewise, the FRET response is demonstrated to be a result of binding to the
phosphorylated IκBα sequence as excess phospho-peptide reduces the FRET response
achieved after incubation with kinase (Figure 4, panel c). Western blot was performed using a
monoclonal phospho(S32/S36)-specific anti-IκBα antibody to demonstrate that the kinase
reaction is efficient and phosphorylation does occur (Figure 4, panel d).
In conclusion, we have demonstrated the utility of mRNA display using a combinatorial protein
library based on the 10FnIII scaffold for modification-specific recognition of protein domains.
We have demonstrated that the selection, combined with solubility evolution, was able to
produce a high-affinity, high-specificity binder to phospho-IκBα. This scaffolded library is
ideally suited to discrimination of modifications due to the flexible, continuous ligand binding
surface generated by the randomized loops (20). We have also demonstrated utility of the
library for binding unstructured epitopes with high affinity. 10C17C25 has been demonstrated
to not only recognize phospho-IκBα in vitro but also to bind and inhibit degradation in vivo.
This intracellular inhibition may prove useful for studying the complex NF-κB pathway as an
alternative to gene knockout or overexpression of modified IκB.
Olson et al. Page 4
ACS Chem Biol. Author manuscript; available in PMC 2010 October 24.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Methods
Reagents
Oligonucleotides were synthesized by IDT or the Yale Keck oligonucleotide synthesis facility.
Oligonucleotide sequences are listed in Supporting Information. Peptides were synthesized by
Biomer-Tech and purified by reverse-phase HPLC. Products were confirmed by electrospray
mass spectrometry. For plasmid construction and cloning, see Supporting Information. E.
coli BL21(DE3) was purchased from Novagen. 293T cells were cultured in Dulbecco's
modified Eagle's medium plus 10% fetal bovine serum (Invitrogen).
Selection
The library used in this selection was previously described (20). Protein-mRNA fusions were
generated as previously described (21). Briefly, each round of selection includes PCR, in
vitro transcription, splint mediated ligation to a 3′ puromycin-containing DNA linker (T4 DNA
ligase, NEB), urea PAGE purification, reticulocyte lysate translation (Red Nova, Novagen),
salt-induced fusion formation, oligo-dT cellulose purification (NEB), reverse transcription
(Superscript II, Invitrogen), and affinity enrichment. For the first round of selection, the 30-
trillion-member library was generated with at least three copies of fusions. Affinity enrichment
was typically performed with 10–20 μL of beads saturated with peptide (neutravidin agarose
or streptavidin ultralink beads, Pierce). The selection buffer included PBS supplemented with
0.5 mg mL−1 BSA (Sigma), 0.1 mg mL−1 sheared salmon sperm DNA (Sigma), 0.02% Tween
20, and 1 mM DTT. A negative selection step was performed beginning at round 6 following
reverse transcription by flowing fusions over ∼100 μL of empty blocked beads in column
format. Free neutravidin or streptavidin (Pierce) was also including in the selection binding
buffer to compete with background binders. Binding was measured by scintillation counting
of 35S-methionine labeled, oligo-dT cellulose purified fusions. All radiolabeled binding assays
were performed at RT. Pool 10 was cloned into a TOPO-TA vector (Invitrogen) for sequencing.
Solubility Evolution
Error-prone PCR was performed with 7 mM MgCl2 and 0.05 mM MnCl2 to generate one or
two mutations per gene. The GFP reporter screen and fluorescence quantitation was carried
out as previously described (20,22). In each round, 24 colonies were picked and assayed prior
to sequencing. In some cases, three or more identical clones had been picked, and these
independent experiments led to standard deviations of 4.1%, 4.0%, and 3.3% for B01, B16,
and C18, respectively. To test retention of function, crude 35S-Methionine labeled, in vitro
translated protein was bound to immobilized target peptide or empty beads, washed, and eluted
with SDS PAGE loading buffer. An equivalent amount of crude translation product, and eluted
protein was analyzed by SDS-PAGE autoradiography to determine percent protein bound.
Surface Plasmon Resonance
SPR was performed on a Biacore T100 instrument (USC NanoBiophysics Core Facility).
10C17C25-MBP was expressed in E. coli BL21(DE3) by induction with 1 mM IPTG at mid-
log phase for 3 h. Pelleted cells were lysed with B-PER (Pierce) and affinity-purified with a
nickel-NTA column (Qiagen), followed by affinity purification with an amylose resin column
(NEB) and desalting (PD-10, Amersham Biosciences). Biacore buffer included PBS plus 0.5
mg mL−1 BSA and 0.05% Tween 20. Various concentrations of analyte were flowed at 100
μL/min for 2 min at RT and allowed to dissociate for 45 min. Binding sensograms were fitted
with Biacore evaluation software.
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Pull-Down
Confluent 293T cell culture was incubated with TNF-α (20 ng mL−1), MG132 (10 μM), and
calyculin A (50 nM), respectively, for 15 min (Calbiochem). Stimulated and unstimulated cells
were lysed for 5 min with ice-cold lysis buffer (PBS, 1% triton x-100, 20 ng mL−1 MG132,
100 nM calyculin A, protease inhibitor cocktail III (Calbiochem), and 1 mM EDTA). MG132
was required during lysis and binding to prevent degradation and depletion of phosphorylated
IκBα. Cell extracts were cleared by centrifugation at 20,000g for 5 min, combined with purified
10C17C25-MBP, and incubated with nickel-NTA beads for 1 h at 4 °C. After three washes,
samples were eluted with PAGE loading buffer. Crude cell extracts from stimulated and
unstimulated cells were run with the eluted samples on SDS-PAGE (NuPAGE system,
Invitrogen), transferred to PVDF membrane (Biorad), and incubated with polyclonal anti-
IκBα (C21) antibody (Santa Cruz Biotechnology). After secondary antibody incubation, blots
were incubated with SuperSignal West Dura substrate (Pierce) and imaged by
chemiluminescence with an Alpha Imager equipped with a cooled CCD camera.
In Vivo Inhibition
293T cells were transiently transfected with 10C17C25-GFP or Fn04-GFP using
Lipofectamine Plus reagent (Invitrogen) following the manufacturers recommendations. One
day post-transfection, cells were stimulated with 20 ng mL−1 TNF-α for the indicated time.
Crude cell extracts were prepared and analyzed by Western blot.
IKK FRET Sensor
FRET sensor proteins were expressed as described for 10C17C25-MBP. Nickel-NTA affinity
purified sensors (50 μg mL−1) were kinased with recombinant IKKβ (1 μg mL−1, Invitrogen)
in 20 mM Tris, pH 7.5 plus 10 mM MgCl2 and 200 μM ATP. Reactions were terminated by
addition of EDTA. Fluorescence emission spectra were obtained using a Shimadzu fluorimeter
RF-5301PC by excitation at 435 nm with 5 nm slit widths. FRET was calculated as the emission
intensity at 525 nm divided by the intensity at 475 nm. Western blot was performed as described
using a monoclonal phospho-IκBα (5A5) antibody (Cell signaling Technology).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Selection of phospho-IκBα binders. a) Enrichment of target binders was monitored by
radiolabeled fusion binding assays. b) Pool 10 binding is sequence-specific and phospho-
specific.
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Figure 2.
Solubility evolution of selection winner using a GFP reporter screen (22). a) Sequence of wild-
type 10FnIII, a pool 10 clone (10C17), and evolved variants of 10C17 from three rounds of
evolution. Dots represent sequence identical to 10C17. b) Total cell fluorescence of expression
cultures relative to wild-type 10FnIII. Proteins were expressed for 4 h (screen 1) or 1.5 h (screen
2). c) Binding of selected clones with in vitro translated protein measured by SDS-PAGE
autoradiography (representative data). d) Locations of evolved mutations on the 10FnIII
surface include solvent-exposed (yellow), buried (green), and AB loop (purple).
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Figure 3.
Affinity and specificity of 10C17C25. SPR was performed to test affinity and specificity to
phospho-IκBα. Concentrations of 10C17C25-MBP ranged from 1–100 nM for phospho-
IκBα binding (panel a) and up to 28 μM for nonphosphorylated IκBα peptide binding (panel
b). Black represents raw data, red represents curve fits. c) Modification-specific binding to
full-length IκBα was determined by pull-down from mammalian cell culture. d) Intracellular
function was demonstrated by the inhibition of IκBα degradation in TNF-α stimulated 293T
cells transiently transfected with 10C17C25-GFP. Cells transiently transfected with
nonselected Fn04-GFP were used as a control.
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Figure 4.
IKK FRET sensor. a) Illustration of a FRET sensor for IKK activity using a designed
modification-specific fibronectin (Fn) binder. b) Four sensors were created, as well as a control
containing nonselected Fn04. The IKK substrate sequence corresponds to IκBα residues 23–
41. c) Representative fluorescence emission spectra of IKK FRET sensors. d) Western blot to
demonstrate both the control and FRET sensor 2L are efficiently phosphorylated by IKK.
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